Mainz, April 28 2016 – “Exploiting Natural Killer cells for immunotherapy of cancer”, PD Dr. rer. nat. Adelheid Cerwenka from the German Cancer Research Center (DKFZ) is visiting TRON.
5 PM, Lecture Hall Building 708, University Medical Center Mainz, Langenbeckstr. 1, 55131 Mainz, Germany
Adelheid Cerwenka is the Head of the Research Group “Innate Immunity” at the German Cancer Research Center in Heidelberg. She received her doctorate from the University of Vienna, Austria, and the Venia Legendi from the Faculty of Medicine, University of Heidelberg. After her 6-year postdoctoral research at the Trudeau Institute New York, USA and UCSF, San Francisco, USA, she became group-leader at the Novartis Research Institute, Vienna before being appointed as independent junior group-leader at the DKFZ. Adelheid Cerwenka is author of more than 75 publications, member of the German Society for Immunology (DGfI), coordinator of the working group “Biology of the NK cell” of the DGfI, member of CIMT and president elect of the Society for Natural Immunity. She serves as reviewer for many high impact journals and national and international grant agencies. In 2008, she was awarded with the Georges Koehler Award of the DGfI. Her research is/was funded by a Marie Curie Excellence Grant and by several grant agencies (e.g. Dt. Krebshilfe and Carreras Foundation).
Research interests are:
- Biology of activating NK cell receptors and their ligands
- Dissecting basic mechanisms of innate immune recognition of tumors by Natural Killer (NK) cells and their modulation by the tumor microenvironment.
- Enhancing NK cell-mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) towards tumors
- Exploiting memory NK cells for cancer therapy
More information about her research interests can be found at: https://www.dkfz.de/en/innateimmun/group_members/mitarbeiter_detail/Cerwenka_Adelheid.html
Information about her publications can be found at: http://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=cerwenka+a%5Bau%5D
Keywords: Natural Killer (NK) cells, immunological memory, adoptive NK cell therapy, cancer therapy